| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10968817 | Vaccine | 2012 | 4 Pages |
Abstract
⺠Sipuleucel-T is the first approved autologous cellular immunotherapy. ⺠It is manufactured from antigen presenting cells obtained via leukapheresis. ⺠Sipuleucel-T has prolonged survival in Phase 3 studies in men with prostate cancer. ⺠Sipuleucel-T elicits robust antigen-specific cellular and humoral immune responses. ⺠Adverse events were generally mild to moderate and resolved within 2 days.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Robert B. Sims,